Vogenx Prices $81.25M IPO at $13.00/Share, Lists on Nasdaq
Summary
Vogenx priced its IPO of 6.25 million shares at $13.00 per share, raising $81.25 million gross. The company will list on Nasdaq under VOGX and use proceeds to advance its lead drug candidate mizagliflozin.
Key Events · Financing and Capital Events · VOGX
-
IPO Priced at $13.00/Share
Vogenx is offering 6,250,000 shares at $13.00 per share, raising $81.25 million in gross proceeds. The underwriters have a 45-day option to purchase up to 937,500 additional shares.
-
Net Proceeds to Fund Clinical Trials
The company estimates net proceeds of $73.6 million after underwriting discounts and expenses. Funds will be used to advance mizagliflozin for PBH through Phase 2b and for gastroparesis through Phase 2 proof of concept.
-
Immediate Dilution for New Investors
New investors will incur immediate dilution of $7.76 per share, the difference between the IPO price and pro forma as adjusted net tangible book value of $5.24 per share.
-
Material Weaknesses and Restatement Disclosed
The prospectus discloses material weaknesses in internal control over financial reporting and a restatement of 2024 and 2025 financial statements to correct net loss per share calculations.
Analysis · VOGX · Life Sciences
A clinical-stage biopharmaceutical company, Vogenx has priced its initial public offering of 6.25 million shares at $13.00 per share, raising $81.25 million in gross proceeds. Net proceeds of approximately $73.6 million are expected, which will fund development of its lead drug candidate mizagliflozin through Phase 2b and Phase 2 trials. The offering is priced at a premium to the company's pro forma net tangible book value, but new investors face immediate dilution of $7.76 per share. The prospectus discloses material weaknesses in internal control over financial reporting, a restatement of prior financial statements, and a going concern uncertainty, which are significant risk factors for investors.
At the time of this filing, VOGX was trading at $12.69 on NASDAQ in the Life Sciences sector. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.